Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease
Digestive and Liver Disease · 2023-08 · 55 (8) · 1034-1041
DOI: 10.1016/j.dld.2022.10.002 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2023-08. Verfasst von Lauranne A A P Derikx und 12 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Radbou…. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Dermatologic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
BACKGROUND: The UNITI trial reports efficacy of ustekinumab (UST) dose intensification in Crohn's disease (CD) from 12- to 8-weekly, but not 4-weekly. We aimed 1) to assess the cumulative incidence of UST dose intensification to 4- or 6-weekly, 2) to identify factors associated with dose intensification, and 3) to assess the effectiveness of this strategy. METHODS: We performed a retrospective, observational cohort study in NHS Lothian including all UST treated CD patients (2015-2020). RESULTS: 163 CD patients were treated with UST (median follow-up: 20.3 months [13.4-38.4]), of whom 55 (33.7%) underwent dose intensification to 4-weekly (n = 50, 30.7%) or 6-weekly (n = 5, 3.1%). After 1 year 29.9% were dose intensified. Prior exposure to both anti-TNF and vedolizumab (HR 9.5; 1.3-70.9), and concomitant steroid use at UST start (HR 1.8; 1.0-3.1) were associated with dose intensification. Following dose intensification, 62.6% patients (29/55) remained on UST beyond 1 year. Corticosteroid-free clinical remission was achieved in 27% at week 16 and 29.6% at last follow-up. CONCLUSION: One third of CD patients treated with UST underwent dose intensification to a 4- or 6-weekly interval within the first year. Patients who failed both anti-TNF and vedolizumab, or required steroids at initiation were more likely to dose intensify.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of…
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; Department of Gastroenterology and Hepatology, Reina Sofía University Hospital, Córdoba, Spain.
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK; Centre for Genomics and Experimental Medicine, Institute of Genetics and…
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Scotland, UK.
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; Centre for Genomics and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK.
Förderung
- Medical Research Council
- Wellcome Trust
Zitieren
APA
Derikx, L. A. A. P., Plevris, N., Su, S., Gros, B., Lyons, M., Siakavellas, S. I., Constantine-Cooke, N., Jenkinson, P., O'Hare, C., Noble, C., Arnott, I. D., Jones, G. R., & Lees, C. W. (2023). Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease. Digestive and Liver Disease, 55(8), 1034-1041. https://doi.org/10.1016/j.dld.2022.10.002
Vancouver
Derikx LAAP, Plevris N, Su S, Gros B, Lyons M, Siakavellas SI, et al. Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease. Digestive and Liver Disease. 2023;55(8):1034-1041. doi:10.1016/j.dld.2022.10.002
BibTeX
@article{Derikx2023,
author = {Derikx, Lauranne A A P and Plevris, Nikolas and Su, Shanna and Gros, Beatriz and Lyons, Mathew and Siakavellas, Spyros I and Constantine-Cooke, Nathan and Jenkinson, Philip and O'Hare, Claire and Noble, Colin and Arnott, Ian D and Jones, Gareth-Rhys and Lees, Charlie W},
title = {Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease},
journal = {Digestive and Liver Disease},
year = {2023},
volume = {55},
number = {8},
pages = {1034--1041},
doi = {10.1016/j.dld.2022.10.002}
}
EUVIMED